(Press-News.org) WASHINGTON — A clinical trial has shown that patients, and their physicians, are eager to jump into next-era cancer care — analysis of an individual's tumor to find and target genetic mutations that drive the cancer. Results of the study, CUSTOM, are being presented at the 2013 annual meeting of the American Society of Clinical Oncology years before investigators thought they would be ready.
CUSTOM is the first completed prospective clinical trial that used genetic analysis alone to assign cancer treatment for patients with one of three different cancers.
"We expected it would take five years to enroll 600 patients into CUSTOM. But in less than two years, 668 patients were recruited," says the study's lead investigator, Giuseppe Giaccone, MD, PhD, associate director for clinical research at Georgetown Lombardi Comprehensive Cancer Center.
"This was a surprise to all of us, especially since patients with advanced cancer who already had biopsies needed to undergo an additional biopsy for the study. But we found patients and their doctors are quite interested in this type of personalized medicine. They know that the molecular profile of the tumor is important," says Giaconne, who is also director of clinical research for the MedStar Georgetown Cancer Network, a regional oncology affiliation between MedStar Health and Georgetown Lombardi.
CUSTOM has proved to be a model for more efficient clinical trials, he adds. It showed that patients want to participate in this kind of research, and that it is feasible to do extensive genetic testing on a tumor biopsy in a timely manner — in this case, taking only two weeks to complete. It also demonstrated that it is safe to take new biopsy from patients with advanced cancer to provide the tissue needed for the analysis.
One of the other endpoints of the study, however, was not achieved. Researchers discovered that, in many cases, they did not have enough patients with rare cancer mutations to provide an accurate statistical analysis of response to novel drugs, says Giaccone.
Giaccone led the clinical trial while at the National Cancer Institute where he was the Chief of the Medical Oncology Branch, before he joined Georgetown in January. Researchers at Oregon Health & Science University also participated.
CUSTOM enrolled patients diagnosed with advanced stage non-small cell lung cancer, small cell lung cancer or thymic cancer. Researchers used next-generation sequencing, which was novel at the time, to look at almost 200 genes. From this, patients were assigned to different treatment groups based on genetic mutations or amplification.
Results from the largest group — patients with non-small cell lung cancer — had either an EGFR or a KRAS mutation, and results showed that those with EGFR mutations had a very high response to the drug erlotinib. "This is nothing new; we essentially confirmed what was already known," Giaccone says. But they also discovered that patients with KRAS mutations did not benefit from the single agent investigational drug selumetinib, which is being studied for use in a number of cancers, including non-small cell lung cancer.
Results for the patients with small cell lung or thymic cancers were inconclusive, primarily because the investigated mutations were rare —not enough patients had specific mutations to adequately test response to therapy. "When we started the study, we didn't know how frequently the mutations occurred," Giaccone says. "Now we know that many mutations represent only 1 to 2 percent of patients and to do this right, you need to screen thousands of patients. That is only possible with a global study that involves, potentially, hundreds of institutions.
"The CUSTOM trial demonstrates both the feasibility of the approach for common mutations — that it is possible to have a real-time genetic analysis that guides treatment — as well as the difficulty of studying treatment for rare mutations," he says.
INFORMATION:
The Intramural Program of the National Cancer Institute funded the study. Giaccone reports having no personal financial interests related to the study.
About Georgetown Lombardi Comprehensive Cancer Center
Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center and MedStar Georgetown University Hospital, seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic and clinical research, patient care, community education and outreach, and the training of cancer specialists of the future. Georgetown Lombardi is one of only 41 comprehensive cancer centers in the nation, as designated by the National Cancer Institute (grant #P30 CA051008), and the only one in the Washington, DC area. For more information, go to http://lombardi.georgetown.edu.
About Georgetown University Medical Center
Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC's mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization (BGRO), which accounts for the majority of externally funded research at GUMC including a Clinical Translation and Science Award from the National Institutes of Health.
END
WASHINGTON — Continuous infusion of a novel agent not only halted the progression of Ewing sarcoma in rats, while some tumors also regressed to the point that cancer cells could not be detected microscopically, say researchers at Georgetown Lombardi Comprehensive Cancer Center. Their study, which will be presented at the 2013 annual meeting of the American Society of Clinical Oncology, provides pre-clinical evidence necessary to initiate a clinical trial.
"This agent has the potential to be more effective, and considerably less toxic, than the current drugs now used to ...
STANFORD, Calif. - In a new study, Stanford University School of Medicine researchers provide the first evidence that African clawed frogs in California harbor a deadly fungal infection that is decimating amphibian populations across the globe.
Among 28 samples tested, the researchers identified three frogs, including one found in Golden Gate Park in San Francisco, that were carriers of the pathogen that has led to the decline or extinction of some 200 amphibian species worldwide. The research was conducted on archived samples from the herpetology collection at the California ...
SEATTLE – People diagnosed with cancer are more than two-and-a-half times more likely to declare bankruptcy than those without cancer, according to a new study from Fred Hutchinson Cancer Research Center. Researchers also found that younger cancer patients had two- to five-fold higher bankruptcy rates compared to older patients, and that overall bankruptcy filings increased as time passed following diagnosis.
The study, led by corresponding author Scott Ramsey, M.D., Ph.D., an internist and health economist at Fred Hutch, was published online on May 15 as a Web First in ...
At a time when the U.S. health system is facing both an increasing demand for primary care services and a worsening shortage of primary care physicians, one broadly recommended strategy has been to increase the number and the responsibilities of nurse practitioners. In 2010 an Institute of Medicine (IOM) committee recommended that "advance practice registered nurses should be able to practice to the full extent of their education and training" and that nurse practitioners should be able to admit patients to hospitals and hospices, lead medical teams and medical homes, and ...
Middle aged and out of shape? It's not too late to get fit — and reduce your risk for heart failure, according to research presented at the American Heart Association's Quality of Care and Outcomes Research Scientific Sessions 2013.
Researchers ranked fitness levels of 9,050 men and women (average age 48) who took two fitness tests — eight years apart — during mid-life. After 18 years of follow-up, they matched the fitness information to Medicare claims for heart failure hospitalizations.
"People who weren't fit at the start of the study were at higher risk for heart ...
Young women tend to be less healthy and have a poorer quality of life than similar-aged men before suffering a heart attack, according to research presented at the American Heart Association's Quality of Care and Outcomes Research Scientific Sessions 2013.
"Compared with young men, women under 55 years are less likely to have heart attacks. But, when they do occur, women are more likely to have medical problems, poorer physical and mental functioning, more chest pain and a poorer quality of life in the month leading up to their heart attack," said Rachel Dreyer, Ph.D., ...
Scientists at the University of California, Davis, detected the H1N1
(2009) virus in free-ranging northern elephant seals off the central
California coast a year after the human pandemic began, according to
a study published today, May 15, in the journal PLOS ONE. It is the
first report of that flu strain in any marine mammal.
"We thought we might find influenza viruses, which have been found
before in marine mammals, but we did not expect to find pandemic
H1N1," said lead author Tracey Goldstein, an associate professor with
the UC Davis One Health Institute and ...
Writing in Nature, a large international team led Dr Roman Gorbachev from The University of Manchester shows that, when graphene placed on top of insulating boron nitride, or 'white graphene', the electronic properties of graphene change dramatically revealing a pattern resembling a butterfly.
The pattern is referred to as the elusive Hofstadter butterfly that has been known in theory for many decades but never before observed in experiments.
Combining graphene with other materials in multiple-layered structures could lead to novel applications not yet explored by ...
A UK-Canadian team of scientists has discovered ancient pockets of water, which have been isolated deep underground for billions of years and contain abundant chemicals known to support life.
This water could be some of the oldest on the planet and may even contain life. Not just that, but the similarity between the rocks that trapped it and those on Mars raises the hope that comparable life-sustaining water could lie buried beneath the red planet's surface.
The findings, published in Nature today, may force us to rethink which parts of our planet are fit for life, ...
A comprehensive analysis of peer-reviewed articles on the topic of global warming and climate change has revealed an overwhelming consensus among scientists that recent warming is human-caused.
The study is the most comprehensive yet and identified 4000 summaries, otherwise known as abstracts, from papers published in the past 21 years that stated a position on the cause of recent global warming – 97 per cent of these endorsed the consensus that we are seeing man-made, or anthropogenic, global warming (AGW)
Led by John Cook at the University of Queensland, the study ...
